Healthcare Realty Trust secures $400M delayed-draw term loan facility
What's the deal? Healthcare Realty Trust has entered into a $400M senior unsecured delayed draw term loan facility maturing in May 2029. The loan features flexible SOFR- or base rate-linked pricing, an accordion option allowing up to $100M in additional capacity, and no mandatory amortisation. The company can draw the capital over a year and prepay without penalty.
Why now? Healthcare Realty is in the middle of a corporate transformation, working to improve operations and lease up its medical office portfolio while carrying elevated debt. The company reaffirmed its 2026 EPS guidance range of -$0.05 to $0.05, signalling it expects to hover around breakeven as it reinvests in its properties.
The facility gives the REIT financial flexibility to manage upcoming obligations without being forced into unfavourable refinancing conditions. Its narrative projects $1.2B in revenue and $220.9M in earnings by 2029 — a $424.7M swing from its current -$203.8M loss position, requiring about 1% annual revenue growth.
What could go wrong? The loan is helpful but not transformational. High leverage and interest costs remain central risks. If asset sales or refinancing plans hit snags, the added debt could worsen an already heavy interest burden.
The company posted a modest net loss in Q1 2026, and the breakeven EPS guidance underscores how thin the margins are. Investors betting on Healthcare Realty need to believe in steady demand for medical office space — a bet that depends on lease-up execution the company has yet to fully prove out.
The signal: Lender willingness to extend a $400M unsecured facility suggests confidence in Healthcare Realty's credit profile, even as the company operates near breakeven. The deal reflects a broader pattern among REITs using flexible debt instruments to buy time for operational turnarounds rather than pursuing dilutive equity raises.
Fair value estimates for the stock range from $20.45 to $27.56 per share, with the lower figure roughly in line with its current price. The gap between those estimates captures the core debate: whether balance sheet flexibility and operational execution can close a $424.7M earnings deficit within three years.
Read more: simplywall.st
